Salud financiera de hoja de balance de Eden Research

Salud financiera controles de criterios 6/6

Eden Research tiene un patrimonio de los accionistas total de £12.7M y una deuda total de £0.0, lo que sitúa su ratio deuda-patrimonio en 0%. Sus activos y pasivos totales son £15.0M y £2.3M respectivamente.

Información clave

Ratio deuda-patrimonio

UK£0

Deuda

Ratio de cobertura de intereses	n/a
Efectivo	UK£4.95m
Patrimonio	UK£12.71m
Total pasivo	UK£2.32m
Activos totales	UK£15.03m

Actualizaciones recientes sobre salud financiera

Recent updates

We Think Eden Research (LON:EDEN) Can Afford To Drive Business Growth

Aug 25

We Think Eden Research (LON:EDEN) Needs To Drive Business Growth Carefully

Jul 09

We're Keeping An Eye On Eden Research's (LON:EDEN) Cash Burn Rate

Mar 05

We Think Eden Research (LON:EDEN) Needs To Drive Business Growth Carefully

Nov 06

Companies Like Eden Research (LON:EDEN) Are In A Position To Invest In Growth

Jul 07

We're Hopeful That Eden Research (LON:EDEN) Will Use Its Cash Wisely

Feb 18

A Look At Eden Research's (LON:EDEN) Share Price Returns

Dec 25

We're Hopeful That Eden Research (LON:EDEN) Will Use Its Cash Wisely

Nov 19

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (£8.7M) de EDEN superan a sus pasivos a corto plazo (£2.3M).

Pasivo a largo plazo: Los activos a corto plazo de EDEN (£8.7M) superan a sus pasivos a largo plazo (£19.6K).

Historial y análisis de deuda-patrimonio

Nivel de deuda: EDEN está libre de deudas.

Reducción de la deuda: EDEN no tenía deudas hace 5 años.

Hoja de balance

Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: EDEN tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.

Pronóstico de cash runway: EDEN dispone de suficiente cash runway para más de 3 años si el flujo de caja libre sigue reduciéndose a tasas históricas de 14.8% cada año

Salud financiera de hoja de balance de Eden Research

Salud financiera controles de criterios 6/6

Información clave

Actualizaciones recientes sobre salud financiera

Eden Research Delists from the OTCQB Exchange in the US

We Think Eden Research (LON:EDEN) Can Afford To Drive Business Growth

We Think Eden Research (LON:EDEN) Needs To Drive Business Growth Carefully

We're Keeping An Eye On Eden Research's (LON:EDEN) Cash Burn Rate

We Think Eden Research (LON:EDEN) Needs To Drive Business Growth Carefully

Companies Like Eden Research (LON:EDEN) Are In A Position To Invest In Growth

Recent updates

New major risk - Financial position

Eden Research Delists from the OTCQB Exchange in the US

First half 2024 earnings released: UK£0.002 loss per share (vs UK£0.015 loss in 1H 2023)

Eden Research plc to Report First Half, 2024 Results on Sep 23, 2024

Eden Research plc Announces Temporary Approval for Cedroz in Greece

Eden Research plc Announces Executive Changes

Eden Research plc Announces Biofungicide Regulatory Authorisation in Germany

Eden Research plc Announces Appointment of Daniel Mulas García as Global Product and Marketing Lead

Eden Research plc Announces Biofungicide Label Extension in Spain

Eden Research plc Appoints Humair Tariq as New Global Commercial Lead

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Eden Research plc to Report Fiscal Year 2023 Results on May 07, 2024

Eden Research plc Announces Appointment of Derek Mcallan as Non-Executive Director and as Chairman of the Audit Committee Following the Company's 2024 AGM

Full year 2023 earnings: EPS and revenues exceed analyst expectations

New minor risk - Financial data availability

Insufficient new directors

Eden Research plc Announces Richard Horsman to Stepped Down as Non-Executive Director

Eden Research plc Provides Revenue Guidance for the Full Year of 2023

First half 2023 earnings released: UK£0.015 loss per share (vs UK£0.003 loss in 1H 2022)

Eden Research plc to Report First Half, 2023 Results on Sep 29, 2023

New major risk - Revenue and earnings growth

We Think Eden Research (LON:EDEN) Can Afford To Drive Business Growth

New minor risk - Shareholder dilution

Eden Research plc Announces Regulatory Application for Authorised Use of Ecovelex™ in the United Kingdom

New major risk - Share price stability

Eden Research plc, Annual General Meeting, Jun 29, 2023

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Eden Research plc to Report Fiscal Year 2022 Results on May 05, 2023

Eden Research plc Announces First Mevalone Authorisation for Domestic Use

Eden Research plc Provides Revenue Guidance for the Full Year of 2022

Less than half of directors are independent

First half 2022 earnings released: UK£0.003 loss per share (vs UK£0.004 loss in 1H 2021)

Eden Research plc Grants US EPA Regulatory Approval

Eden Research plc Appoints Richard Horsman as Non-Executive Director, with effect from 1 September 2022

We Think Eden Research (LON:EDEN) Needs To Drive Business Growth Carefully

Eden Research plc, Annual General Meeting, Jun 29, 2022

Full year 2021 earnings: EPS exceeds analyst expectations while revenues lag behind

Eden Research plc Announces Progress Towards EPA Approval and Further Authorisation in Italy

Insufficient new directors

We're Keeping An Eye On Eden Research's (LON:EDEN) Cash Burn Rate

We Think Eden Research (LON:EDEN) Needs To Drive Business Growth Carefully

First half 2021 earnings released: UK£0.004 loss per share (vs UK£0.004 loss in 1H 2020)

Eden Research plc Announces New Label Extension for Biofungicide in Portugal

Companies Like Eden Research (LON:EDEN) Are In A Position To Invest In Growth

Full year 2020 earnings released: UK£0.007 loss per share (vs UK£0.005 loss in FY 2019)

New 90-day high: UK£0.20

We're Hopeful That Eden Research (LON:EDEN) Will Use Its Cash Wisely

A Look At Eden Research's (LON:EDEN) Share Price Returns

We're Hopeful That Eden Research (LON:EDEN) Will Use Its Cash Wisely

First half earnings released

Eden Research plc Announces New Authorisations for Cedroz™ and Mevalone®

Análisis de la situación financiera

Historial y análisis de deuda-patrimonio

Hoja de balance

Análisis de cash runway

Descubre empresas con salud financiera